Spectrum Pharmaceuticals has not received the FDA approval for the supplementary marketing application for its advanced metastatic colorectal cancer drug Fusilev. Fusilev is already approved for use after high-dose methotrexate therapy in osteosarcoma. It is also approved to decrease the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent over dosage of folic acid antagonists.